Max Healthcare posts strong Q2 and half-year financial growth

Max Healthcare Institute Ltd. announced a robust financial performance for Q2 FY26, with network gross revenue soaring to ₹2,692 Cr, a 21% year-over-year increase. Network operating EBITDA grew by 23% to ₹694 Cr, and PAT surged by 59% to ₹554 Cr. This impressive growth reflects strong operational leverage and increased occupied bed days. For the half-year ended September 30, 2025, network gross revenue reached ₹5,266 Cr, a 24% YoY growth, with operating EBITDA at ₹1,308 Cr, up 23% YoY.

Key operational highlights include an increase in bed capacity to 4,760 and a 77% occupancy rate. Max Lab revenue grew by 16% YoY to ₹54 Cr, while Max@Home revenue increased by 20% YoY to ₹63 Cr. The company divested hospitals in Village Chitta and Anoopshahr to focus on super-specialty care in larger cities. The NCLT Chandigarh Bench approved the merger of JHL and CRL, which favorably impacted tax.

Max Healthcare also continued its focus on clinical excellence, performing 3,989 liver transplants, 5,276 kidney transplants, and 2,151 bone marrow transplants. Research and academics saw significant activity, with 88 scientific publications and 121 clinical trials ongoing. The company remains committed to expanding its footprint and enhancing healthcare delivery across India.